Oramed Pharmaceuticals (ORMP) Operating Expenses (2011 - 2026)

Oramed Pharmaceuticals has reported Operating Expenses for 15 years, with the latest figure at $3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 18.92% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $14.2 million (down 0.59% YoY), and the FY2025 full-year result was $15.1 million, up 18.15% from the prior year.
• Operating Expenses for Q1 2026 stood at $3.7 million, down from $5.7 million in the prior quarter.
• The five-year high for Operating Expenses was $11.8 million in Q4 2022, with the low at $2.4 million in Q3 2025.
• Historically, Operating Expenses has averaged $5.4 million across 5 years, with a median of $3.9 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Expenses sank 67.04% — and 2025, when it jumped 57.77%.
• Oramed Pharmaceuticals' Operating Expenses stood at $11.8 million in 2022, then slumped by 67.04% to $3.9 million in 2023, then retreated by 7.27% to $3.6 million in 2024, then jumped by 57.77% to $5.7 million in 2025, then sank by 35.49% to $3.7 million in 2026.
• The last three Operating Expenses figures came in at $3.7 million (Q1 2026), $5.7 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.